Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Ortho Tri-Cyclen · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm A - Ortho Tri-Cyclen® | ACTIVE_COMPARATOR | 1 to 28 days |
| Arm B - Ortho Tri-Cyclen® | ACTIVE_COMPARATOR | 29 to 56 days |
| Arm C - Ortho Tri-Cyclen® + BMS-650032 | ACTIVE_COMPARATOR | Ortho Tri-Cyclen®: 57 to 77 days BMS-650032: 68 to 77 days |
| Name | Type | Description |
|---|---|---|
| Ortho Tri-Cyclen® | DRUG | Tablets, Oral, 1 Tablet, once daily |
| BMS-650032 | DRUG | Tablets, Oral, 600 mg, BID |
Inclusion Criteria: * Healthy Females, 18-40 years, BMI 18 - 32kg/m². Must use an acceptable method of contraception to avoid pregnancy throughout the study and 8 weeks after last dose of study drug Exclusion Criteria: * Abnormal pap smear within 1 year prior to day 1 * Any significant or chronic...
Ortho Tri-Cyclen is an investigational small molecule being studied for use in Hepatitis C Virus. It is being evaluated in a Phase 1 clinical trial that examines its interaction with an oral contraceptive pill in healthy female volunteers. The drug is not approved and remains in clinical development.
Ortho Tri-Cyclen is being developed by Bristol-Myers Squibb Company, which trades under the ticker BMY. The company is conducting clinical research on this drug for Hepatitis C Virus, with one completed Phase 1 trial involving 20 participants.
Ortho Tri-Cyclen is in Phase 1 clinical development. It is an investigational drug for Hepatitis C Virus and has not been approved by regulatory authorities. One Phase 1 trial has been completed, and the drug remains in the early stages of clinical testing.
Ortho Tri-Cyclen has been studied in one clinical trial registered as NCT01063023, titled "Drug Interaction Oral Contraceptive Pill (OCP)." This Phase 1 study was completed in the United States and enrolled 20 healthy female volunteers aged 18 years and older. The trial was active-controlled and not randomized or double-blind.
Ortho Tri-Cyclen is being studied for its potential interaction with oral contraceptive pills in the context of Hepatitis C Virus treatment. The clinical trial specifically evaluates how this drug interacts with an oral contraceptive, but no alternative names for Ortho Tri-Cyclen itself have been established in the research data.